[go: up one dir, main page]

SMT202000305T1 - Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle - Google Patents

Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle

Info

Publication number
SMT202000305T1
SMT202000305T1 SM20200305T SMT202000305T SMT202000305T1 SM T202000305 T1 SMT202000305 T1 SM T202000305T1 SM 20200305 T SM20200305 T SM 20200305T SM T202000305 T SMT202000305 T SM T202000305T SM T202000305 T1 SMT202000305 T1 SM T202000305T1
Authority
SM
San Marino
Prior art keywords
wounds
disorders
diseases
skin
compositions
Prior art date
Application number
SM20200305T
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000305(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of SMT202000305T1 publication Critical patent/SMT202000305T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SM20200305T 2016-04-08 2016-12-28 Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle SMT202000305T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08
EP16826873.8A EP3377637B1 (en) 2016-04-08 2016-12-28 Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin
PCT/US2016/068974 WO2017176336A1 (en) 2016-04-08 2016-12-28 Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

Publications (1)

Publication Number Publication Date
SMT202000305T1 true SMT202000305T1 (it) 2020-07-08

Family

ID=57822104

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200305T SMT202000305T1 (it) 2016-04-08 2016-12-28 Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle

Country Status (23)

Country Link
US (7) US9877990B2 (it)
EP (2) EP3712273A1 (it)
JP (3) JP6970086B2 (it)
KR (2) KR20250133993A (it)
CN (1) CN109072255A (it)
AU (5) AU2016401692B2 (it)
CA (1) CA3017487A1 (it)
CL (3) CL2018002814A1 (it)
CY (1) CY1123024T1 (it)
DK (1) DK3377637T3 (it)
ES (1) ES2796488T3 (it)
HR (1) HRP20200853T1 (it)
HU (1) HUE049237T2 (it)
LT (1) LT3377637T (it)
MX (2) MX394867B (it)
NZ (1) NZ778381A (it)
PL (1) PL3377637T3 (it)
PT (1) PT3377637T (it)
RS (1) RS60410B1 (it)
SG (1) SG11201808314QA (it)
SI (1) SI3377637T1 (it)
SM (1) SMT202000305T1 (it)
WO (1) WO2017176336A1 (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CA3017487A1 (en) 2016-04-08 2017-10-12 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
CN110312506A (zh) * 2016-11-14 2019-10-08 密歇根大学董事会 用于阻挡紫外线辐射的组合物和方法
SG11201906213UA (en) 2017-01-10 2019-08-27 Intrexon Corp Modulating expression of polypeptides via new gene switch expression systems
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
AU2019252658B2 (en) 2018-04-12 2023-09-14 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
SG11202009895TA (en) * 2018-04-27 2020-11-27 Krystal Biotech Inc Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2020006486A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
CA3112633A1 (en) * 2018-09-26 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
AU2020209687A1 (en) * 2019-01-18 2021-07-29 Osaka University Composition for use in treating dystrophic epidermolysis bullosa
CN113454105A (zh) * 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
CN114401769A (zh) * 2019-03-27 2022-04-26 菲尼克斯组织修复公司 生产胶原蛋白7组合物的系统和方法
AU2020341451A1 (en) * 2019-09-03 2022-03-24 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
WO2023064806A1 (en) 2021-10-12 2023-04-20 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
AU2024255842A1 (en) * 2023-04-13 2025-11-06 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye
CN119751645A (zh) * 2024-12-31 2025-04-04 北京华熙荣熙生物技术研究有限公司 一种重组ⅶ型胶原蛋白及其制备方法和应用
CN119685407A (zh) * 2025-02-25 2025-03-25 北京唯源立康生物科技股份有限公司 工程化单纯疱疹病毒载体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
EP0973538B1 (en) * 1997-04-10 2008-03-12 University of Southern California Modified proteins which bind extracellular matrix components
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999064094A1 (en) * 1998-06-12 1999-12-16 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
WO2000040734A1 (en) * 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
AU2001235829A1 (en) * 2000-03-02 2001-09-12 Isis Innovation Limited Mutations in spink5 responsible for netherton's syndrome and atopic diseases
DE60131569T2 (de) * 2000-11-28 2008-10-23 The University Of Chicago, Chicago Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen
JP4212897B2 (ja) * 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
EP1487983A4 (en) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer PREVENTING THE REPEAT AND METASTASIS OF CANCER
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP2377882A1 (en) * 2004-10-28 2011-10-19 University of Pittsburgh of the Commonwealth System of Higher Education Peripherally delivered glutamatic acid decarboxylase gene therapy for spinal cord injury pain
PL2289535T3 (pl) * 2004-12-21 2018-12-31 Musc Foundation For Research Development Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek
RU2007131689A (ru) * 2005-01-21 2009-02-27 Интроджен Тетрапьютикс, Инк. (Us) Местное введение терапевтических и профилактических нуклеиновых кислот, обеспечивающее их пролонгированное действие на клетки-мишени
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
EP1885186B1 (en) * 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009105690A2 (en) * 2008-02-21 2009-08-27 Targeted Genetics Corporation Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
KR101746872B1 (ko) * 2009-05-22 2017-06-14 제노시아 바이오사이언스, 인크. 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
EP2766480B1 (en) * 2011-10-11 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
JP2015520754A (ja) * 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
ES2750550T3 (es) * 2013-03-01 2020-03-26 Univ Minnesota Corrección de gen a base de TALEN
MX365409B (es) * 2013-03-14 2019-05-31 Shire Human Genetic Therapies Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
EP3022307A4 (en) * 2013-07-17 2017-04-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
ES2810800T3 (es) * 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
EP3690056B1 (en) 2014-01-31 2022-12-28 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
BR112017008805A2 (pt) * 2014-10-31 2017-12-19 Kyoto Prefectural Public Univ Corp tratamento de córnea usando laminina
CA2976376A1 (en) * 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
EP3795180B1 (en) * 2015-12-14 2025-11-05 The Trustees of The University of Pennsylvania Gene therapy for ocular disorders
JP2019508063A (ja) * 2016-01-27 2019-03-28 オンコラス， インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
EP3432905B1 (en) * 2016-03-25 2022-06-01 PeriphaGen, Inc. Hsv vectors for delivery of nt3 and treatment of cipn
EP3432912B1 (en) * 2016-03-25 2022-12-21 PeriphaGen, Inc. High-transducing hsv vectors
CA3017487A1 (en) 2016-04-08 2017-10-12 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AU2019252658B2 (en) 2018-04-12 2023-09-14 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
SG11202009895TA (en) 2018-04-27 2020-11-27 Krystal Biotech Inc Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2020006486A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
RS60410B1 (sr) 2020-07-31
DK3377637T3 (da) 2020-05-18
HRP20200853T1 (hr) 2020-08-21
EP3377637A1 (en) 2018-09-26
NZ746213A (en) 2021-08-27
AU2025204575A1 (en) 2025-07-10
SI3377637T1 (sl) 2020-08-31
AU2016401692B2 (en) 2019-10-03
CY1123024T1 (el) 2021-10-29
LT3377637T (lt) 2020-07-10
PL3377637T3 (pl) 2020-09-07
US20190160122A1 (en) 2019-05-30
KR20250133993A (ko) 2025-09-09
US20220273737A1 (en) 2022-09-01
AU2016401692A1 (en) 2018-09-27
ES2796488T3 (es) 2020-11-27
JP2023118838A (ja) 2023-08-25
US9877990B2 (en) 2018-01-30
CL2021000881A1 (es) 2021-09-10
JP2022023174A (ja) 2022-02-07
AU2019280069B2 (en) 2022-04-07
AU2025200334B2 (en) 2025-04-17
JP6970086B2 (ja) 2021-11-24
AU2022204729A1 (en) 2022-07-21
HUE049237T2 (hu) 2020-09-28
US10155016B2 (en) 2018-12-18
US20230414686A1 (en) 2023-12-28
WO2017176336A1 (en) 2017-10-12
CA3017487A1 (en) 2017-10-12
MX394867B (es) 2025-03-24
NZ778381A (en) 2025-07-25
AU2025200334A1 (en) 2025-02-20
US11865148B2 (en) 2024-01-09
US20180169160A1 (en) 2018-06-21
JP2019513689A (ja) 2019-05-30
US10441614B2 (en) 2019-10-15
US20200101123A1 (en) 2020-04-02
PT3377637T (pt) 2020-06-17
US20230149486A1 (en) 2023-05-18
CL2018002814A1 (es) 2019-02-15
AU2022204729B2 (en) 2025-02-06
EP3712273A1 (en) 2020-09-23
JP7480105B2 (ja) 2024-05-09
SG11201808314QA (en) 2018-10-30
AU2019280069A1 (en) 2020-01-16
US20170290866A1 (en) 2017-10-12
EP3377637B1 (en) 2020-03-18
KR20180128016A (ko) 2018-11-30
CL2023000743A1 (es) 2023-09-29
MX2022006072A (es) 2022-06-14
CN109072255A (zh) 2018-12-21
US11185564B2 (en) 2021-11-30
MX2018012135A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
SMT202000305T1 (it) Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
IL270978B (en) Grape skin for use in the treatment of dysbiosis
PL3722291T3 (pl) Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
SI3307277T1 (sl) Enoverižni oligonukleotidi za uporabo pri zdravljenju motenj kože
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
IL246855A0 (en) Materials for use in the treatment of retinitis
SMT202100070T1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
HK1260224A1 (en) Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
AU2016900442A0 (en) PAK1-blocking esters, preparation, and their use in treatment of cancer and other PAK1-dependent diseases/disorders
HK40007519A (en) Vaccines for use in treating various diseases and disorders
HK40027056A (en) Grape skin for use in the treatment of dysbiosis
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases